|
|
Locally
delivered chemotherapy and repeated surgery can improve survival in glioblastoma
patients
Boiardi A, Eoli M, Pozzi A, Salmaggi A, Broggi G,
Silvani A
Department
of Neurology, National Neurologic Institute C. Besta, Milano, Italy
We
treated 54 patients, newly diagnosed for glioblastoma, with systemic
chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks)
and radiotherapy soon after surgery.
In 10 cases the treatment was combined with locoregional chemotherapy (1 mg
bleomycin on days 1-2, and 3 mg mitoxantrone on day 3, repeated every 20 days)
administered from an Ommaya reservoir.
At tumor recurrence, all patients were treated with procarbazine, lomustine and
vincristine (PCV); 15 of 54 were reoperated and treated with locoregional
chemotherapy.
The median time to disease progression (TTP) and overall survival time (ST) for
the whole group were 10.8 and 23.1 months, respectively.
The ST of the 15 reoperated patients who also received locoregional treatment at
disease recurrence was 27.6 months; this was significantly longer than that of
patients not reoperated and not treated locally (log-rank p=0.04).
The results in our reoperated subgroup support the opinion that a second
operation could be suitable if it is part of the whole program of treatment.
PMID:
10933484 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10933484&dopt=Abstract
|
